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In treatment of metabolic imbalances caused by maple syrup urine disease (MSUD), peritoneal dialysis, and hemofiltration,
pharmacological treatments for elimination of toxicmetabolites can be used in addition to basic dietarymodifications.Therapywith
sodiumphenylacetate/benzoate or sodiumphenylbutyrate (NaPB) in urea-cycle disorder cases has been associatedwith a reduction
in branched-chain amino acid (BCAA) concentrations when the patients are on adequate dietary protein intake. Moreover, NaPB
in treatment of MSUD patients is also associated with reduction of BCAA levels in a limited number of cases. However, there
are not enough studies in the literature about application and efficacy of this treatment. Our case report sets an example of an
alternative treatment’s efficacy when extracorporeal procedures are not available due to technical difficulties during attack period
of the disease.
1. Introduction
Maple syrup urine disease (MSUD) is an autosomal recessive
inherited metabolic disease caused by decreased enzyme
activity of branched-chain alpha-ketoacid dehydrogenase
complex (BCKDC), responsible for catabolism of leucine
(leu), valine (val), and isoleucine (isoleu). Global known inci-
dence rate of this condition is 1 in 185000 [1]. BCKCD is a 4-
million Daltonmacromolecule and consists of heterodimeric
E1 decarboxylase component (E1a and E1b subunits), E2
transacylase that consists of 24 subunits and 1 homodimer E3
component [2]. The condition shows in five different clinical
phenotypes as classic, intermediate, intermittent, thiamine-
responsive and E3 deficiency type [3].
Formerly, studies have shown that a drop in plasma
branched-chain amino acid levels in cases with urea-cycle
metabolismdisorders can be obtainedwith sodiumphenylac-
etate/benzoate or sodium phenylbutyrate (NaPB) treatments
[4, 5]. Following the path of these studies, new studies about
using nitrogen scavenging agents inMSUDpatients to reduce
branched-chain amino acid levels are also in progress [6].
However, as with all branched-chain amino acid metabolism
disorders, extracorporeal methods are still the first line
of choice in treatment of encephalopathy caused by acute
decompensation [7].
In this article, our main aim is to share our experience
in a MSUD patient under hemodialysis for acute metabolic
decompensation using Na phenylacetate/benzoate followed
by NaPB to reduce the increased branched-chain amino acid
levels after stopping hemodialysis for technical reasons.
2. Case
A 2-day-old male infant was hospitalized in pediatric inten-
sive care unit with encephalopathy findings of repetitive
myoclonic convulsions, hypertonicity, and pedaling. The
parents of the infant were first-degree cousins. The patient
had deep metabolic acidosis and his plasma amino acid
levels were leu: 5933 𝜇mol/l (𝑁: 33–124), isoleu: 1440 𝜇mol/l
(𝑁: 27–110) (NR for appropriate age), val: 1345 𝜇mol/l (𝑁:
30–125), and urine organic acid result was 3-Ketoisocaproic
acid 1328mmol/molCrea. A genetic analysis for MSUD was
performed following these results and a homozygote muta-
tion on DNT gene IVS7-1G>A was found. Leu levels of the
patient were reduced to normal ranges after 72 hours of suc-
cessful hemodialysis. Moreover, ketoacid exertion through
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urine was also significantly reduced following hemodialysis.
Patient was treated with isoleu, leu, and val-free formula and
10mg/day thiamine. Despite seeing no complete elimination
in urine ketoacid during 4 weeks of thiamine treatment
and blood leucine levels showing a wavy pattern against
dietary modifications, thiamine treatment was increased up
to 200mg/day step by step. However, patient showed no
response to thiamine treatment. Following initial decom-
pensation attack, medical supportive treatments were used
during increases in blood leucine, valine, and isoleucine levels
during infections for 19 months’ follow-up period. Patient
had normal development during follow-up period and his
weight was 75–90 p, height was 90–97 p, circumference of
head was in 25–30 percentile, unassisted sitting was possible
and speaking 1-2 words in 19/12 months.
On 19 months of age patient was taken to emergency
department for emesis, reduction in oral intake, and sleepi-
ness. His physical examination during initial admission
showedmoderate dehydration and lethargy. Laboratory anal-
yses were consistent with metabolic acidosis and hyperam-





: 212mmol/l). He has been treated by high-
dextrose fluid and intralipids (glucose: 14.5mcg/kg/min,
lipid: 3 gr/kg/day, and l-carnitine 100mg/kg/day) following
an initial intravenous fluid bolus. In addition, patient received
continuous nasogastric infusion of BCAA-free formula as
well as isoleucine and valine supplements to promote leucine
incorporation into newly synthesized proteins. Over the last 6
hours, patient’s neurological status deteriorated progressively
with decreased levels of consciousness and decreased motor
reflexes. CT scans showed no cerebral edemas within brain.
Hemodialysis was ordered after seeing the patient’s blood
amino acid levels (leu: 2948𝜇mol/l (𝑁: 33–124), isoleu:
438 𝜇mol/l (𝑁: 27–110), and val: 1345 𝜇mol/l (𝑁: 30–125))
with the patient in encephalopathy state.The patient has been
transferred to intensive care unit and connected to a ventila-
tor. Eight Fr double-lumen hemodialysis catheter was placed
into femoral vein and continuous venovenous hemodialysis
(CVVHD) was started. Patient’s blood amino acid levels
and urine organic acid levels were analyzed every 2 hours.
Leucine levels were reduced to 328𝜇mol/l after 24 hours of
hemodialysis. On 28th hour of hemodialysis, patient had a
fever and he had infection criteria but infection focus could
not be detected. Hemodialysis was paused after this infection
situation and simultaneous clogging of femoral catheter.
Blood leucine level of patient rose to 1100𝜇mol/l on 4th
hour of stopping hemodialysis. Status epilepticus was seen
in patient with generalized tonic-clonic convulsions. Bedside
electroencephalogram showed generalized epileptic activity
and control brain CT showed no brain edema. Midazolam
and levetiracetam infusions were started. Since extracor-
poreal elimination treatments cannot be performed at this
stage, patient was loaded with Na phenylacetate/Na benzoate
(Ammonul %10/%10 50ml), with a dosage of 250mg/kg for 2
hours, and then 250mg/kg/24-hour infusion, based on pre-
vious studies on reducing branched-chain amino acid levels
in urea-cycle disorder patients using Na phenylacetate/Na
benzoate and NaPB [4–6]. Blood leu-isoleu and val levels













Figure 1: Hemodialysis andNa phenylacetate/benzoate and phenyl-
butyrate treatment during attack management. 0–28 hrs: Contin-
ious venovenous dialysis (through femoral vein) 28. hr: Cloggling
of hemodialysis catheter, 32–66. hrs: Na phenylacetate/benzoate,
66. hrs+: Na phenylbutyrate (Pheburane 483mg/gr, granulated).
checked every 4 hours. Patient regained full consciousness
following 24-hour infusion of Na phenylacetate/Na Benzoate
infusion and his blood leucine level was 521 𝜇mol/l. Na
phenylacetate/Na benzoate treatment was stopped at the
24th hour. NaPB was started enterally through nasogastric
tube with 500mg/kg/day dosage after Na phenylacetate/Na
benzoate had been stopped in order to continue leu levels
constantly in normal ranges.On 36th hour blood leucine level
was 321𝜇mol/l and patient was separated from the mechan-
ical ventilator. After 12 hours of follow-up, Patient’s BCAA
and BCKA levels were shown on Figure 1. Patient was
discharged following NaPB treatment and BCAA-restricted
dietary modifications on 17th day of admission. Phebu-
rane (483mg/gr, granulated) was chosen since it was taste-
masked and odor-free with a dosage of 500mg/kg/day. His
branched-chain amino acid levels were kept down within
normal values under NaPB treatment during hospitalization.
During discharge of the patient, neurological examination
showed spasticity of lower extremity so baclofen treatment
was started. In 1-year follow-up, branched-chain amino acid
levels of the patient were within normal range (Table 1).
Natural protein intake of the patient was increased in his
diet under NaPB treatment and his dependency on the
diet was reduced (Table 2). No attacks were seen. Spasticity
completely improved and patient had ordered walking and
speech with 9-10 words in 2 years and 5 months of age. After
one year follow-up his weight was 50–75 p, height was 90 p,
circumference of head was in 25 percentile.
3. Discussion
Sodium phenylacetate/sodium benzoate and NaPB are alter-
native pathways for excretion of waste nitrogen in urea-
cycle disorders using endogenous biosynthetic pathways to
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Table 1: Values of plasma leucine, isoleucine, valine, alanine, glutamine, glycine, and ammonia during periods of therapy.
Normal values 0–19 months NaPB 17th day (discharging) NaPB 3 months NaPB 6 months NaPB 12 months
Leucine (𝜇mol/L) 33–124 422 ± 25,8 108 142 167 138
Isoleucine (𝜇mol/L) 27–110 78 ± 34,2 92 87 52 67
Valine (𝜇mol/L) 30–125 176 ± 28,1 98 101 119 121
Alanine (𝜇mol/L) 54–250 34 ± 54,7 234 207 267 283
Glutamine (𝜇mol/L) 80–450 198 ± 49,5 267 199 301 276
Glycine (𝜇mol/L) 50–230 436 ± 38,1 182 178 167 176
Ammonia (𝜇mol/L) <70 111 ± 28,1 101 77 63 92





















Leu (mg/day) 336 360 0 360 360 390 420 450
Isoleu (mg/day) 161 298 300 290 290 342 390 410
Valine (mg/day) 158 287 300 280 280 300 320 330
Protein
(gr/kg/day) 2,7 2,5 2,5 2,9 2,95 2,8 2,85 2,92
Energy
(Kcal/day) 110 kcal/kg/day 1198 1400 1300 1450 1580 1620 1700
eliminate nonurea waste nitrogen as a substitute for defective
urea synthesis. They work by stimulating nitrogen excretion
as phenylacetylglutamine and hippuric acid. Phenylbutyrate
does not accumulate in plasma and converted into pheny-
lacetate which is its active form. It is then conjugated with
glutamine in liver and kidney to form phenylacetylglutamine
which is excreted in urine, replacing urea as a mean of
eliminating excess nitrogen compounds [4, 5, 8].
One of the hypotheses that explain the reduction of
BCAA levels using NaPB and Na phenylacetate is that
overproduction of phenylacetylglutamine depletes glutamine
reserves and secondarily reduces BCAA levels [5]. In vitro
and animal studies showed that active metabolite of NaPB
increased BCKDC complex activity by inhibiting phosphory-
lation of E1a subunit and its inactivation, which is responsible
for breakdown of BCAA [6, 9]. In a 5-person group of
both classic and late-onset MSUD cases, patients were given
NaPB for treatment and 3 out of 5 showed a significant
decrease in branched-chain amino acid levels independent
of residual BCKDH activity [6]. This response sparked
interest in using NaPB as a recent approach in treatment
of MSUD, which has no pharmacological treatment method
apart from thiamine-responsive form. A randomized double
blind placebo controlled study is underway to investigate
whether NaPB may be an effective therapy for patients with
MSUD (ClinicalTrials.gov Identifier: NCT01529060).
The genetic analysis of our patient revealedIVS7-IG>A
mutation inDBT gene. DBT gene is responsible for coding E2
subunit of BCKDC and its molecular phenotype is compati-
ble with Type II MSUD [1]. As known, there is a strong cor-
relation between thiamine-responsive MSUD with mutant
E2 protein [3] but since our patient did not respond to a
gradual thiamine treatment from 10mg/day to 200mg/day, he
was deemed as thiamine-unresponsive [10]. Patient’s BCKDC
enzyme levels could not be measured; however, his clinical
presentation showed that his clinical phenotype is compatible
with classicMSUD [1, 3]. Brunetti-pierri et al. [6] showed that
NaPB’s effect is mainly on E1a subunit of BCKDC; however
the same study showed a significantly reduced level in BCAA
levels following NaPB treatment in both patients with E2
mutations. However, up to now, there is no data about using
sodium phenylacetate/sodium benzoate andNaPB effectively
in a MSUD patient during an acute decompensation attack.
In our patient, a speedy and efficient drop in BCAA levels
was obtained using sodium phenylacetate/sodium benzoate
during attack phase and hemodialysis had to be stopped
due to technical reasons. In addition, NaPB treatment was
continued after the attack and patient’s dependency to diet
was reduced to an extent and natural protein intake was
increased after 1-year of follow-up (Table 2).
4. Conclusion
It is a known fact that sodium phenylbutyrate usage increases
enzyme activity of alpha-ketoacid dehydrogenase, effectively
decreasing blood branched-chain amino acid levels. How-
ever, there is still not enough data on the usage and efficacy
of sodium phenylbutyrate during MSUD attack periods.
The case we discussed here in our paper could be possibly
interpreted as the first example of an alternative attack
management method in situations where extracorporeal
procedures are not available due to technical reasons.
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Written informed consent was obtained from the patient’s
parents for publication of this case report and any accompa-
nying images.
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